The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity

European Journal of Medicinal Chemistry

Volumn 112, Issue , 2016, Pages 20-32

  Newton, Rebecca ^a   Bowler, Katherine A ^a   Burns, Emily M ^b   Chapman, Philip J ^a   Fairweather, Emma E ^a   Fritzl, Samantha J R ^a   Goldberg, Kristin M ^a   Hamilton, Niall M ^a   Holt, Sarah V ^a   Hopkins, Gemma V ^a   Jones, Stuart D ^a   Jordan, Allan M ^a   Lyons, Amanda J ^a   Nikki March, H ^a   McDonald, Neil Q ^b,c   Maguire, Laura A ^a   Mould, Daniel P ^a   Purkiss, Andrew G ^b   Small, Helen F ^a   Stowell, Alexandra I J ^a   Thomson, Graeme J ^a   Waddell, Ian D ^a   Waszkowycz, Bohdan ^a   Watson, Amanda J ^a   Ogilvie, Donald J ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Kinase; Quinazoline; RET

Indexed keywords

3 ((6,7 DIMETHOXYQUINAZOLIN 4 YL)AMINO) 4 FLUORO 2 METHYLPHENOL; ANILINE DERIVATIVE; PHENOL DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN RET;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; LIVER CELL; MALE; METABOLIC CLEARANCE; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR DOCKING;

ANIMALS; CELL LINE; DRUG DESIGN; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES;

EID: 84958025669     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.01.039     Document Type: Article

References (27)

1. E. Arighi, M.G. Borrello, and H. Sariola RET tyrosine kinase signaling in development and cancer Cytokine Growth Factor Rev. 16 2005 441 467
2. S.A. Wells Jr., B.G. Robinson, R.F. Gagel, H. Dralle, J.A. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J.R. Vasselli, J. Read, P. Langmuir, A.J. Ryan, and M.I. Schlumberger Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J. Clin. Oncol. 30 2012 134 141
3. R. Elisei, M.J. Schlumberger, S.P. Mueller, P. Schoffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, and S.I. Sherman Cabozantinib in progressive medullary thyroid cancer J. Clin. Oncol. 31 2013 3639 3646
4. A. Drilon, L. Wang, A. Hasanovic, Y. Suehara, D. Lipson, P. Stephens, J. Ross, V. Miller, M. Ginsberg, M.F. Zakowski, M.G. Kris, M. Ladanyi, and N. Rizvi Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas Cancer Discov. 3 2013 630 635
5. O. Gautschi, T. Zander, F.A. Keller, K. Strobel, A. Hirschmann, S. Aebi, and J. Diebold A patient with lung adenocarcinoma and RET fusion treated with vandetanib J. Thorac. Oncol. 8 2013 e43 44
6. A. Coxon, J. Bready, S. Kaufman, J. Estrada, T. Osgood, J. Canon, L. Wang, R. Radinsky, R. Kendall, P. Hughes, and A. Polverino Anti-tumor activity of motesanib in a medullary thyroid cancer model J. Endocrinol. Invest. 35 2012 181 190
7. N.A. Pennell, G.H. Daniels, R.I. Haddad, D.S. Ross, T. Evans, L.J. Wirth, P.H. Fidias, J.S. Temel, S. Gurubhagavatula, R.S. Heist, J.R. Clark, and T.J. Lynch A phase II study of gefitinib in patients with advanced thyroid cancer Thyroid 18 2008 317 323
8. R. Perez-Soler, J.P. Delord, A. Halpern, K. Kelly, J. Krueger, B.M. Sureda, J. von Pawel, J. Temel, S. Siena, D. Soulieres, L. Saltz, and J. Leyden HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncol. 10 2005 345 356
9. L.M. Mulligan RET revisited: expanding the oncogenic portfolio Nat. Rev. Cancer 14 2014 173 186
10. P.P. Knowles, J. Murray-Rust, S. Kjaer, R.P. Scott, S. Hanrahan, M. Santoro, C.F. Ibanez, N.Q. McDonald, Structure, and Chemical Inhibition of the RET tyrosine kinase domain J. Biol. Chem. 281 2006 33577 33587
11. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, R. Chester, J.A. Jackson, S.J. Boffey, P.J. Valentine, J.O. Curwen, H.L. Musgrove, G.A. Graham, G.D. Hughes, A.P. Thomas, E.S.E. Stokes, B. Curry, G.H.P. Richmond, P.F. Wadsworth, A.L. Bigley, and L.F. Hennequin ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res. 62 2002 4645 4655
12. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, G. Vecchio, A.J. Ryan, G. Fontanini, A. Fusco, and M. Santoro ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res. 62 2002 7284 7290
13. A.P. Thomas, L.F.A. Hennequin, and C. Johnstone S.A. Zeneca Pharma, Thomas Andrew Peter, Hennequin Laurent Francois Andre, Johnstone Craig, Preparation of 4-Anilinoquinazolines for use in the Treatment of Disease States Associated with Antiangiogenesis and/or Increased Vascular Permeability 1997 Zeneca Ltd. UK 72pp.
14. A.J. Barker Quinazoline tyrosine kinase-inhibiting anticancer agents 1993 Zeneca Ltd. UK 99pp.
15. M.R. Myers, N.N. Setzer, A.P. Spada, A.L. Zulli, C.-Y.J. Hsu, A. Zilberstein, S.E. Johnson, L.E. Hook, and M.V. Jacoski The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: inhibitors of p56lck and EGF-R tyrosine kinase activity Bioorg. Med. Chem. Lett. 7 1997 417 420
16. P.A. Ple, T.P. Green, L.F. Hennequin, J. Curwen, M. Fennell, J. Allen, C. Lambert-van der Brempt, and G. Costello Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src J. Med. Chem. 47 2004 871 887
17. A.P. Thomas, C. Johnstone, and L.F.A. Hennequin S.A. Zeneca Pharma, Thomas Andrew Peter, Johnstone Craig, Hennequin Laurent Francois Andre, Preparation of quinazolines as VEGF inhibitors 1997 Zeneca Ltd. UK 102pp.
18. L.F. Hennequin, A.P. Thomas, C. Johnstone, E.S.E. Stokes, P.A. Ple, J.-J.M. Lohmann, D.J. Ogilvie, M. Dukes, S.R. Wedge, J.O. Curwen, J. Kendrew, and C. Lambert-van der Brempt Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors J. Med. Chem. 42 1999 5369 5389
19. M.E. Krolski, A.F. Renaldo, D.E. Rudisill, and J.K. Stille Palladium-catalyzed coupling of 2-bromoanilines with vinylstannanes. A regiocontrolled synthesis of substituted indoles J. Org. Chem. 53 1988 1170 1176
20. J. Feutrill, C. Leriche, and D. Middlemiss Preparation of bi-aryl derivatives as EP2 agonists useful in treating glaucoma 2013 Fovea Pharm. Fr. 17pp
21. R.L. Cournoyer, P.F. Keitz, C. O'Yang, and D.M. Yasuda Preparation of arylsulfonamides and urea derivatives and their use as alpha 1A/1L adrenoceptor agonists 1998 F. Hoffmann-La Roche A.-G. Switz. 120pp.
22. R.M. Soll, C. Guinosso, and A. Asselin Multigram preparation of 1,8-diethyl-7-hydroxy-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, a phenolic metabolite of the analgesic and antiinflammatory agent etodolac J. Org. Chem. 53 1988 2844 2847
23. A.F. Kreft, D.H. Klaubert, S.C. Bell, T.W. Pattison, J.P. Yardley, R.P. Carlson, J.M. Hand, J.Y. Chang, and A.J. Lewis Novel 1,3-bis(aryloxy)propanes as leukotriene D4 antagonists J. Med. Chem. 29 1986 1134 1138
24. S.J. Shuttleworth, A.J. Folkes, I.S. Chuckowree, N.C. Wan, T.C. Hancox, S.J. Baker, S. Sohal, and M.A. Latif Preparation of fused pyrimidines as inhibitors of phosphatidylinositol 3 kinase (PI3 kinase) 2006 Piramed Ltd. UK 113pp.
25. S.-K. Anandan, H.K. Webb, Z.N. Do, and R.D. Gless Unsymmetrical non-adamantyl N,N′-diaryl urea and amide inhibitors of soluble epoxide hydrolase Bioorg. Med. Chem. Lett. 19 2009 4259 4263
26. G.Q. Daley, and D. Baltimore Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein Proc. Natl. Acad. Sci. U. S. A. 85 1988 9312 9316
27. D. Lipson, M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, J.A. Curran, S. Balasubramanian, T. Bloom, K.W. Brennan, A. Donahue, S.R. Downing, G.M. Frampton, L. Garcia, F. Juhn, K.C. Mitchell, E. White, J. White, Z. Zwirko, T. Peretz, H. Nechushtan, L. Soussan-Gutman, J. Kim, H. Sasaki, H.R. Kim, S.-I. Park, D. Ercan, C.E. Sheehan, J.S. Ross, M.T. Cronin, P.A. Jaenne, and P.J. Stephens Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat. Med. (N. Y., N. Y. U. S.) 18 2012 382 384